Publications for 2021
Matsumoto T, Darlington O, Miller R, Gordon J, McEwan P, Ohashi T, Taie A, Yuasa A. Estimating the Economic and Clinical Value of Reducing Antimicrobial Resistance to Three Gram-negative Pathogens in Japan. JHEOR. 2021;8(2):64-75. doi:10.36469/001c.28327
Shiri T, Evans M, Talarico CA, Morgan AR, Mussad M, Buck PO, McEwan P, Strain WD. Vaccinating Adolescents and Children Significantly Reduces COVID-19 Morbidity and Mortality across All Ages: A Population-Based Modeling Study Using the UK as an Example. Vaccines. 2021; 9(10):1180. https://doi.org/10.3390/vaccines9101180
Darlington O, Dickerson C, Evans M, McEwan P, Sörstadius E, Sugrue D, van Haalen H, Garcia Sanchez JJ. Costs and Healthcare Resource Use Associated with Risk of Cardiovascular Morbidity in Patients with Chronic Kidney Disease: Evidence from a Systematic Literature Review. Adv Ther. 2021 Jan 11. doi: 10.1007/s12325-020-01607-4. Online ahead of print.
Bem D, Sugrue D, Wilding B, Zile I, Butler K, Booth D, Tafesse E, McEwan P. The effect of hyperkalemia and long inter-dialytic interval on morbidity and mortality in patients receiving hemodialysis: a systematic review. Renal Failure. 2021 Jan 1;43(1):241-54.
Rozenbaum MH, Large S, Bhambri R, Stewart M, Whelan J, van Doornewaard A, Dasgupta N, Masri A, Nativi-Nicolau J. Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review. Cardiol Ther. 2021 Apr 20. doi: 10.1007/s40119-021-00219-5. Epub ahead of print. PMID: 33877591
One Hundred Years of Insulin: Value Beyond Price in Type 2 Diabetes Mellitus
Evans M, Morgan AR, Bain SC. One Hundred Years of Insulin: Value Beyond Price in Type 2 Diabetes Mellitus. Diabetes Ther. 2021 Apr 26:1–12. doi: 10.1007/s13300-021-01061-7.
Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors
Evans M, Morgan AR, Yousef Z, Ellis G, Dashora U, Patel DC, Brown P, Hanif W, Townend JN, Kanumilli N, Moore J, Wilding JPH, Bain SC. Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors. Drugs. 2021 Jun 23. doi: 10.1007/s40265-021-01538-6. Epub ahead of print. PMID: 34160822.
Butler K, Anderson SJ, Hayward O, Jacob I, Punekar YS, Evitt LA, Oglesby A. Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States. J Manag Care Spec Pharm. 2021 Jul;27(7):891-903. doi: 10.18553/jmcp.2021.27.7.891. PMID: 34185564.
Gordon J, Stainthorpe A, Jones B, Jacob I, Hertel N, Diaz J, Yuan Y, Borrill J. Non-Price-Related Determinants of Value and Access for Novel Non-small Cell Lung Cancer Treatments: A Cross-Country Review of HTA Decision Making. Pharmacoecon Open. 2021 Jul 2. doi: 10.1007/s41669-021-00279-2. Epub ahead of print. PMID: 34216002.
The Value of Insulin Degludec in Frail Older Adults with Type 2 Diabetes
Strain WD, Morgan AR, Evans M. The Value of Insulin Degludec in Frail Older Adults with Type 2 Diabetes. Diabetes Ther. 2021 Oct 4. doi: 10.1007/s13300-021-01162-3. Epub ahead of print. PMID: 34608609.
Publications for 2020
Tafesse E, Hurst M, Hoskin L, Badora K, Sugrue D, Qin L, James G, McEwan P. Risk factors associated with the incidence and recurrence of hyperkalaemia in patients with cardiorenal conditions. Int J Clin Pract. 2020 Dec 17:e13941. doi: 10.1111/ijcp.13941. Online ahead of print.
McEwan P, Morgan AR, Boyce R, Bergenheim K, Gause-Nilsson I, Bhatt D, Leiter LA, Johansson PA, Mosenzon O, Cahn A, Wilding J. The cost-effectiveness of dapagliflozin in treating high risk patients with type 2 diabetes mellitus: an economic evaluation using data from the DECLARE-TIMI 58 trial. Diabetes Obes Metab. 2020 Dec 28. doi: 10.1111/dom.14308. Online ahead of print.
Evans, M., Morgan, A.R., Patel, D. et al. Risk Prediction of the Diabetes Missing Million: Identifying Individuals at High Risk of Diabetes and Related Complications. Diabetes Ther (2020). https://doi.org/10.1007/s13300-020-00963-2
Tafesse E, Hurst M, Sugrue D, Hoskin L, Badora K, Qin L, James G, McEwan P. Serum Potassium As A Predictor Of Adverse Clinical Outcomes In Patients With Increasing Comorbidity Burden. Eur Heart J Qual Care Clin Outcomes. 2020 Oct 20:qcaa078. doi: 10.1093/ehjqcco/qcaa078. Epub ahead of print. PMID: 33079171.
Hill NR, Arden C, Beresford-Hulme L, Camm AJ, Clifton D, Davies DW, Farooqui U, Gordon J, Groves L, Hurst M, Lawton S, Lister S, Mallen C, Martin AC, McEwan P, Pollock KG, Rogers J, Sandler B, Sugrue DM, Cohen AT. Identification of undiagnosed atrial fibrillation patients using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI): Study protocol for a randomised controlled trial. Contemp Clin Trials. 2020 Oct 19;99:106191. doi: 10.1016/j.cct.2020.106191. Epub ahead of print. PMID: 33091585; PMCID: PMC7571442.
McEwan P, Bennett H, Khunti K, et al. Assessing the cost-effectiveness of SGLT2i in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real-world evidence [published online ahead of print, 2020 Aug 3]. Diabetes Obes Metab. 2020;10.1111/dom.14162.
McEwan P, Darlington O, McMurray JJV, et al. Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF [published online ahead of print, 2020 Aug 4]. Eur J Heart Fail. 2020;10.1002/ejhf.1978. doi:10.1002/ejhf.1978
Sekelj S, Sandler B, Johnston E, et al. Detecting undiagnosed atrial fibrillation in UK primary care: Validation of a machine learning prediction algorithm in a retrospective cohort study [published online ahead of print, 2020 Aug 13]. Eur J Prev Cardiol. 2020;2047487320942338. doi:10.1177/2047487320942338
Lei S, Willis M, Asseburg C, Nilsson A, Tew M, Clarke P, Lamotte M, Ramos M, Shao H, Shi L, Zhang P, McEwan P, Ye W, Herman W, Kuo S, Isaman DJ, Schramm W, Sailer F, Brennan A, Pollard D, Smolen H, Leal J, Gray A, Patel R, Feenstra T, Palmer A. Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge. Value in Health. 2020 August 6.
Hill NR, Sandler B, Mokgokong R, Lister S, Ward T, Boyce R, Farooqui U, Gordon J. Cost-effectiveness of targeted screening for the identification of patients with atrial fibrillation: Evaluation of a machine learning risk prediction algorithm. Journal of Medical Economics. 2019 Dec 18.
Hill NR, Sandler B, Bergrath E, Milenković D, Ashaye AO, Farooqui U, Cohen AT. A systematic review of network meta-analyses and real-world evidence comparing Apixaban and Rivaroxaban in Nonvalvular Atrial Fibrillation. Clinical and Applied Thrombosis/Hemostasis. 2020 Jan 10.
Ward T, Sugrue D, Hayward O, McEwan P, Anderson SJ, Lopes S, Punekar Y. Oglesby A. Estimating HIV Management and Comorbidity Costs Among Aging HIV Patients in the United States: A Systematic Review. Journal of Managed Care and Speciality Pharmacy. 2020 Feb;26(2):104-116.
Bennett H, Tank A, Evans M, Bergenheim K, McEwan P. Cost‐effectiveness of dapagliflozin as an adjunct to insulin for the treatment of Type 1 Diabetes Mellitus in the UK. Diabetes, Obesity and Metabolism. 2020 Feb 9.
Jacob I, Butler K, Badora K, Gross, V, Beiderbeck, A, Morris S, McEwan P. Comment on ‘Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal’. PharmacoEconomics. 2020 April 6.
Gordon J, Darlington O, McEwan P, Lumley M, Taie A, Hicks M, Charbonneau C, Blake A, Hawkins N, Goldenberg S, Otter J, Wilcox M. Estimating the Value of New Antimicrobials in the Context of Antimicrobial Resistance: Development and Application of a Dynamic Disease Transmission Model. PharmacoEconomics. 2020 April 6.
Gordon J, Danne T, Beresford-Hulme L, Bennet H, Tank A, Edmonds C, Thorén F, Scheerer MF, McEwan P. Adverse Changes in HbA1c, Body Weight and Insulin Use in People with Type 1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme. Diabetes Therapy: Research, Treatment and Education of Diabetes and Related Disorders. 2020 Apr 9.
What Next After Metformin in Type 2 Diabetes? Selecting the Right Drug for the Right Patient
Strain WD, Tsang C, Hurst M, McEwan P, Unadkat M, Meadowcroft S, Shardlow R, Evans M. What Next After Metformin in Type 2 Diabetes? Selecting the Right Drug for the Right Patient. Diabetes Ther. 2020 May 18. doi: 10.1007/s13300-020-00834-w. Online ahead of print.
Gordon J, Beresford-Hulme L, Bennett H, Tank A, Edmonds C, McEwan P.Relationship Between Hypoglycaemia, Body Mass Index and Quality of Life Among Patients With Type 1 Diabetes: Observations From the DEPICT Clinical Trial Programme. Diabetes Obes Metab. 2020 May;22(5):857-865. doi: 10.1111/dom.13972.
Gibson EJ, Begum N, Koblbauer I, Dranitsaris G, Liew D, McEwan P, Yuan Y, Juarez-Garcia A, Tyas D, Pritchard C. Economic Evaluation of Single versus Combination Immuno-Oncology Therapies: Application of a Novel Modelling Approach in Metastatic Melanoma. Clinicoecon Outcomes Res. 2020;12:241-252. doi.org/10.2147/CEOR.S238725
Palaka E, Grandy S, van Haalen H, McEwan P, Darlington O. The Impact of CKD Anaemia on Patients: Incidence, Risk Factors, and Clinical Outcomes - A Systematic Literature Review. International Journal of Nephrology. Volume 2020. Article ID 7692376. doi.org/10.1155/2020/7692376
Hawkins R, Fife K, Hurst M, Wang M, Naicker N, Nolasco S, Eisen T, Matakidou A, Gordon J. Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK. BMC Cancer. 2020;20(1):670. Published 2020 Jul 17. doi:10.1186/s12885-020-07154-z
Publications for 2019
Pochopien M, Beiderbeck A, McEwan P, Zur R, Toumi M, Aballéa S. Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies. BMC Health Services Research. 2019 Dec;19(1):22.
Linde C, Qin L, Bakhai A, Furuland H, Evans M, Ayoubkhani D, Palaka E, Bennett H, McEwan P. Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK. ESC heart failure. 2019 Jan 10.
The value of maintaining normokalaemia and enabling RAASi therapy in Chronic Kidney Disease
Evans M, Palaka E, Furuland H, Bennett H, Linde C, Qin L, McEwan P, Bakhai A. The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease. BMC nephrology. 2019 Dec;20(1):31.
Bennett H, McEwan P, Hamilton K, O'Reilly K. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD. BMC Nephrology. 2019 Apr 23;20(1):136.
Kent S, Becker F, Feenstra T, Tran-Duy A, Schlackow I, Tew M, Zhang P, Ye W, Lizheng S, Herman W, McEwan P. The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood. PharmacoEconomics. 2019:1-8.
Strain WD, McEwan P, Howitt H, Meadowcroft S. Retrospective Database Analysis Evaluating the Clinical Outcomes of Changing Treatment of People with Type 2 Diabetes Mellitus (T2DM) from Other DPP-4 Inhibitor Therapy to Alogliptin in a Primary Care Setting. Diabetes Therapy. 2019 Jul 1:1-9.
Gibson EJ, Begum N, Koblbauer I, Dranitsaris G, Liew D, McEwan P, Yuan Y, Juarez-Garcia A, Tyas D, Pritchard C. Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma. Journal of medical economics. 2019 Mar 1:1-4.
Foos V, Wang K, McEwan P, Zhang Y, Xin P, Jiang X, Qu S, Xiong T, De Moor R, Ramos M, Lamotte M. Assessing the burden of type 2 diabetes in China considering the current status-quo management and implications of improved management using a modeling approach. Value in health regional issues. 2019 May 1;18:36-46.
Lacoin L, Hurst M, Hill NR,, Gordon J, Geretti AM, Aspinall R, Corless L, Gao-Du Y, Mistry L, Mutimer D. Evolution of the burden of active hepatitis C virus infection in England from September 2015 to September 2016: a repeated cross-sectional analysis. BMJ Open. 2019 August 5; 9(8).
What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer?
Evans M, Morgan AR, Yousef Z. What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer?. Diabetes Therapy. 2019 Aug 1:1-3.
Associations between serum potassium and adverse clinical outcomes: a systematic literature review
Palaka E, Grandy S, Darlington O, McEwan P, van Doornewaard A. Associations between serum potassium and adverse clinical outcomes: a systematic literature review. International journal of clinical practice. 2019 Sep 18.
Sugrue DM, Ward T, Rai S, McEwan P, van Haalen HGM. Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design. Pharmacoeconomics. 2019 Sep 30.
Kaloyannidis P, Hertzberg M, Webb K, Zomas A, Schrover R, Hurst M, Jacob I, Nikoglou T, Connors JM. Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation. British journal of haematology. 2019 Oct 6.
Predicting Atrial Fibrillation in Primary Care Using Machine Learning
Hill NR, Ayoubkhani D, McEwan P, Sugrue DM, Farooqui U, Lister S, Lumley M, Bakhai A, Cohen AT, O'Neill M, Clifton D, Gordon J. Predicting atrial fibrillation in primary care using machine learning. PLoS One. 2019 Nov 1;14(11):e0224582.
Linde C, Bakhai A, Furuland H, Evans M, McEwan P, Ayoubkhani D, Qin L. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom. J Am Heart Assoc. 2019 Nov 19;8(22):e012655.
Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
Evans M, Hicks D, Patel D, Patel V, McEwan P, Dashora U. Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes Therapy. Diabetes Therapy. 2019 Dec 7; 10.1007/s13300-019-00728-6 [Epub ahead of print].
Publications for 2018
McEwan P, Wilton HB, Ong AC, Ørskov B, Sandford R, Scolari F, Cabrera MC, Walz G, O’Reilly K, Robinson P. A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model. BMC nephrology. 2018 Dec;19(1):37.
McEwan P, Bennett H, Bolin K, Evans M, Bergenheim K. Assessing the economic value of maintained improvements in Type 1 diabetes management, in terms of HbA1c, weight and hypoglycaemic event incidence. Diabetic Medicine. 2018 May;35(5):557-66.
Gibson EJ, Begum N, Koblbauer I, Dranitsaris G, Liew D, McEwan P, Monfared AT, Yuan Y, Juarez-Garcia A, Tyas D, Lees M. Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes. ClinicoEconomics and outcomes research: CEOR. 2018;10:139.
Prospective utility study of patients with multiple cardiovascular events
Pockett RD, McEwan P, Ray J, Tran I, Shutler S, Martin S, Yousef Z, Bakhai A. Prospective utility study of patients with multiple cardiovascular events. Journal of medical economics. 2018 Jun 3;21(6):616-21.
Gordon J, McEwan P, Idris I, Evans M, Puelles J. Treatment choice, medication adherence and glycemic efficacy in people with type 2 diabetes: a UK clinical practice database study. BMJ Open Diabetes Research and Care. 2018 May 1;6(1):e000512.
Chen W, Ward T, Tan MP, Yan J, Wang PF, Wygant GD, Gordon J. Daclatasvir combined with asunaprevir is a cost-effective and cost-saving treatment for hepatitis C infection in China. Journal of comparative effectiveness research. 2018 Jun 4(0).
Furuland H, McEwan P, Evans M, Linde C, Ayoubkhani D, Bakhai A, Palaka E, Bennett H, Qin L. Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink. BMC nephrology. 2018 Dec;19(1):211.
Bakhai A, Palaka E, Linde C, Bennett H, Furuland H, Qin L, McEwan P, Evans M. Development of a health economic model to evaluate the potential benefits of optimal serum potassium management in patients with heart failure. Journal of medical economics. 2018 Sep 13:1-1.
Publications for 2017
Fathi H, Clark A, Hill NR, Dusheiko G. Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review. BMC infectious diseases. 2017 Dec;17(1):722.
Bennett H, Gordon J, Jones B, Ward T, Webster S, Kalsekar A, Yuan Y, Brenner M, McEwan P. Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies. The European Journal of Health Economics. 2017 Nov 1;18(8):1001-11.
McEwan P, Webster S, Ward T, Brenner M, Kalsekar A, Yuan Y. Estimating the cost-effectiveness of daclatasvir+sofosbuvir versus sofosbuvir+ribavirin for patients with genotype 3 hepatitis C virus. Cost Eff Resour Alloc. 2017 Jul 21;15:15
Ward T, Webster S, Mishina S, McEwan P, Wygant G, Wang P Assessing the Budget Impact and Economic Outcomes of the Introduction of Daclatasvir + Asunaprevir and Sofosbuvir/Ledipasvir for the Treatment of Chronic Hepatitis C Virus Infection in Japan. Value Health Reg Issues. 2017 May;12:1-6
Gordon J, McEwan P, Evans M, Puelles J. Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care-based cohort study, with economic assessment of patient outcomes. Diabetes Obes Metab. 2017 May; 19(5): 644–653
An alternative approach to modelling HbA1c trajectories in patients with type 2 diabetes mellitus
McEwan P, Bennett H, Qin L, Bergenheim K, Gordon J, Evans M. An alternative approach to modelling HbA1c trajectories in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2017 May;19(5):628-634
McEwan P, Selvapatt N, Brown A, Thursz M, Bennett H, Webster S, Kalsekar A, Yuan Y, Brenner M and Gordon J. A clinician’s guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective. Eur J Gastroenterol Hepatol. 2017 Feb;29(2):208-214
Kim DY, Han K-H, Jun B, Kim TH, Park S, Ward T, Webster S, McEwan P. Estimating the cost effectiveness of the implementation of a hepatitis C screening and treatment programme in South Korea. PLoS One. 2017; 12(1)
Ward T, Gordon J, Jones B, Bennett H, Webster S, Kalsekar A, Yuan Y, Brenner M, McEwan P. Value of Sustained Virologic Response in Patients with Hepatitis C as a Function of Time to Progression of End-Stage Liver Disease. Clin Drug Investig. 2017 Jan;37(1):61-70
The cost impact of outreach testing and treatment for hepatitis C in an urban Drug Treatment Unit.
Selvapatt N, Ward T, Harrison L, Lombardini J, Thursz M, McEwan P, Brown A.The cost impact of outreach testing and treatment for hepatitis C in an urban Drug Treatment Unit. Liver Int. 2017 Mar;37(3):345-353
Publications for 2016
McEwan P, Ward T, Webster S, Yuan Y, Kalsekar A, Kamae I, Kobayashi M, Tang A, Kumada H. Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b. Hepatol Res. 2016 Mar;46(5):423-33.
Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea
Kim DY, Han KH, Jun B, Kim TH, Park S, Ward T, Webster S, McEwan P. Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea.
PLoS One. 2017 Jan 6;12(1)
McEwan P, Selvapatt N, Brown A, Thursz M, Bennett H, Webster S, Kalsekar A, Yuan Y, Brenner M, Gordon J. A clinician’s guide to the cost and health benefits
of hepatitis C cure assessed from the individual patient perspective. Eur J Gastroenterol Hepatol. 2017 Feb;29(2):208-214.
Ward T, Gordon J, Jones B, Bennett H, Webster S, Kalsekar A, Yuan Y, Brenner M, McEwan P. Value of Sustained Virologic Response in Patients with Hepatitis C as a Function of Time to Progression of End-Stage Liver Disease. Clin Drug Investig. 2017 Jan;37(1):61-70.
Gordon J, McEwan P, Evans M, Puelles J, Sinclair A. Managing glycaemia in older people with type 2 diabetes: a retrospective, primary care based cohort study, with economic assessment of patient outcomes. Diabetes Obes Metab. 2016 Dec 27.
An alternative approach to modelling HbA1c trajectories in patients with type 2 diabetes mellitus
McEwan P, Bennett H, Qin L, Bergenheim K, Gordon J, Evans M. An alternative
approach to modelling HbA1c trajectories in patients with type 2 diabetes
mellitus. Diabetes Obes Metab. 2016 Dec 27. doi: 10.1111/dom.12865. [Epub ahead
of print] PubMed PMID: 28026908.
Ward T, Gordon J, Bennett H, Webster S, Sugrue D, Jones B, Brenner M, McEwan Tackling the burden of the hepatitis C virus in the UK: characterizing and
assessing the clinical and economic consequences. Public Health. 2016 Dec;141:42-51.
Bennett H, Gordon J, Jones B, Ward T, Webster S, Kalsekar A, Yuan Y, Brenner M, McEwan P. Hepatitis C disease transmission and treatment uptake: impact on the
cost-effectiveness of new direct-acting antiviral therapies. Eur J Health Econ. 2016 Nov 1.
Gordon J, McEwan P, Hurst M, Puelles J. The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus. Diabetes Ther. 2016 Dec;7(4):825-845.
McEwan P, Bennett H, Fellows J, Priaulx J, Bergenheim K. The Health Economic Value of Changes in Glycaemic Control, Weight and Rates of Hypoglycaemia in Type
1 Diabetes Mellitus. PLoS One. 2016 Sep 15;11(9)
Davies MJ, Glah D, Chubb B, Konidaris G, McEwan P. Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting. Pharmacoeconomics. 2016 Sep;34(9):953-66.
Gordon J, McEwan P, Sabale U, Kartman B, Wolffenbuttel BH. The cost-effectiveness of exenatide twice daily (BID) vs insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes. J Med Econ. 2016 Dec;19(12):1167-1174.
McEwan P, Bennett H, Ward T, Webster S, Gordon J, Kalsekar A, Yuan Y, Brenner. The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK. Eur J Gastroenterol Hepatol. 2016 Feb;28(2):173-80.
Charokopou M, Sabater FJ, Townsend R, Roudaut M, McEwan P, Verheggen BG. Methods applied in cost-effectiveness models for treatment strategies in type 2 diabetes mellitus and their use in Health Technology Assessments: a systematic review of the literature from 2008 to 2013. Curr Med Res Opin. 2016;32(2):207-18.
Publications for 2015
Refitting of the UKPDS 68 Risk Equations to Contemporary Routine Clinical Practice Data in the UK
McEwan P, Bennett H, Ward T, Bergenheim K. Refitting of the UKPDS 68 Risk Equations to Contemporary Routine Clinical Practice Data in the UK Pharmacoeconomics 2015; 33(2):149-61
McEwan P, Gordon J, Evans M, Ward T, Bennett H, Bergenheim K. Estimating Cost-Effectiveness in Type 2 Diabetes: The Impact of Treatment Guidelines and Therapy Duration Med Decis Making 2015
Sabale U, Ekman M, Granstrom O, Bergenheim K, McEwan P. Cost-effectiveness of dapagliflozin (Forxiga((R))) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries Prim Care Diabetes 2015; 9(1):39-47
Foos V, Varol N, Curtis BH, Boye KS, Grant D, Palmer JL, McEwan P. Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United States. J Med Econ. 2015; (1):1-39
McEwan P, Ward T, Bennett H, Kalsekar A, Webster S, Brenner M, Yuan Y. Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C. PLoS One 2015; 10(1):e0117334
McEwan P, Larsen Thorsed B, Wolden M, Jacobsen H, Evans M. Healthcare resource implications of hypoglcaemia-related hospital admissions and inpatient hypoglycaemia: retrospective record-linked cohort studies in England. BMJ Open Diabetes Res Care 2015; 3(1):e000057
Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K, Postema R, Townsend R, Roudaut M. The cost-effectiveness of dapaglifozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus. Diabet Med. 2015; doi: 10.1111/dme.12772
Gordon JP, McEwan PC, Maguire A, Sugrue DM, Puelles J.. Characterising unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn’s disease: a systematic review and clinician surveys. Eur J Gastroenterol Hepatol. 2015; 27(7):804-12
Bennett H, McEwan P, Sugrue D, Jalsekar A, Yuan Y.. Assessing the long-tem impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the relationship between treatment uptake and efficacy on future infections. PLoS One. 2015; 10(5):e0125846
Clinical and cost-effectiveness of insulin degludec: from clinical trials to clinical practice
Evans M, McEwan P.. Clinical and cost-effectiveness of insulin degludec: from clinical trials to clinical practive. J Comp Eff Res. 2015; 11:1-8 [Epub ahead of print]
Selvapatt N, Ward T, Bailer H, Bennett H, Thorne C, See LM, Tudor-Williams G, Thurz M, McEwan P, Brown A. Is antenatal screening for hepatitis C virus cost effective? A decade’s experience at a London centre. J Hepatol. 2015; doi: 10.1016/j.jhep.2015.05.015 [Epub ahead of print]
Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model
McEwan P, Ward T, Bennett H, Bergenheim K. Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model. Cost Eff Resour Alloc. 2015 Aug 4;13:12.
Pockett RD, Watkins J, McEwan P, Meier G. Burden of Illness in UK Subjects with Reported Respiratory Infections Vaccinated or Unvaccinated against Influenza: A Retrospective Observational Study. PLoS One. 2015;10(8):e0134928.
McEwan P, Ward T, Webster S, Yuan Y, Kalsekar A, Kamae I, Kobayashi M, Tang A, Kumada H. Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b. Hepatol Res. 2015 doi: 10.1111/hepr.12570. [Epub ahead of print]
Gordon JP, Evans M, Puelles J, McEwan PC. Factors Predictive of Weight Gain and Implications for Modeling in Type 2 Diabetes Patients Initiating Metformin and Sulfonylurea Combination Therapy. Diabetes Ther. 2015. [Epub ahead of print]
Publications for 2014
Review of utility values for economic modeling in type 2 diabetes
Beaudet A, Clegg J, Thuresson PO, Lloyd A, McEwan P. Review of utility values for economic modeling in type 2 diabetes Value Health 2014; 17(4):462-70
Assessment of Unmet Clinical Need in Type 2 Diabetic Patients on Conventional Therapy in the UK
Bennett H, McEwan P, Bergenheim K, Gordon J. Assessment of Unmet Clinical Need in Type 2 Diabetic Patients on Conventional Therapy in the UK. Diabetes Ther 2014; 5(2):567-7
The economic burden of posttransplant events in renal transplant recipients in Europe
Chamberlain G, Baboolal K, Bennett H, Pockett RD, McEwan P, Sabater J, Sennfalt K. The economic burden of posttransplant events in renal transplant recipients in Europe Transplantation 2014; 97(8):854-61
Evans M, McEwan P, Foos V. Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice-a case-based evaluation J Med Econ 2014; p1-10
Evans M, McEwan P, O’Shea R, George L. Efficacité en pratique clinique courante des incrétino-mimétiques dans le traitement du diabète de type 2 : résultats d’une enquête nationale rétrospective au Royaume-Uni Médecine des Maladies Métaboliques 2014; 8(2):177-83
Validation of the IMS CORE Diabetes Model
McEwan P, Foos V, Palmer JL, Lamotte M, Lloyd A, Grant D. Validation of the IMS CORE Diabetes Model Value Health 2014; 17(6):714-24
McEwan P, Ward T, Chen C-J, Lee M-H, Yang H-I, Kim R, L’Italien G, Yuan Y. Estimating the Incidence and Prevalence of Chronic Hepatitis C Infection in Taiwan Using Back Projection Value in Health Regional Issues 2014; 3(0):5-11
McEwan P, Ward T, Webster S, Yuan Y, Kalsekar A, Broglio K, Kamae I, Quintana M, Berry SM, Kobayashi M, Inoue S, Tang A, Kumada H. Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b Value in Health Regional Issues 2014; 3(0):136-45
van Haalen HG, Pompen M, Bergenheim K, McEwan P, Townsend R, Roudaut M. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands Clin Drug Investig 2014; 34(2):135-46
Publications for 2013
Evans M, McEwan P, O’Shea R, George L. A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice Diabetes Ther 2013; 4(1):27-40
Evans M, McEwan P, O’Shea R, George L, Svendsen C, Clarke A. Case note survey of T2D patients prescribed incretin therapies according to current recommendations in clinical practice Prim Care Diabetes 2013; 7(1):83
Evaluation of insulin use and value for money in type 2 diabetes in the United Kingdom
Gordon J, Evans M, McEwan P, Bain S, Vora J. Evaluation of insulin use and value for money in type 2 diabetes in the United Kingdom Diabetes Ther 2013; 4(1):51-66
McEwan P, Kim R, Yuan Y. Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model Appl Health Econ Health Policy 2013; 11(1):53-63
McEwan P, Ward T, Yuan Y, Kim R, L’Italien G. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States Hepatology 2013; 58(1):54-64
Palmer AJ, Clarke P, Gray A, Leal J, Lloyd A, Grant D, Palmer J, Foos V, Lamotte M, Hermann W, Barhak J, Willis M, Coleman R, Zhang P, McEwan P, Betz Brown J, Gerdtham U, Huang E, Briggs A, Carlsson KS, Valentine W. Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting Value Health 2013; 16(4):670-85
Publications for 2012
Erhardt W, Bergenheim K, Duprat-Lomon I, McEwan P. Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis Clin Drug Investig 2012; 32(3):189-202
A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain
Gordon J, Lister S, Prettyjohns M, McEwan P, Tetlow A, Gabriel Z. A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain J Med Econ 2012; 15(2):207-18
Monitoring progress in the management of hip fractures in South Australia, Australia
Gordon J, Pham CT, Karnon J, Crotty M. Monitoring progress in the management of hip fractures in South Australia, Australia Arch Osteoporos 2012; 7(1-2):267-73
Cost-effectiveness of saxagliptin (Onglyza(R)) in type 2 diabetes in Sweden
Granstrom O, Bergenheim K, McEwan P, Sennfalt K, Henriksson M. Cost-effectiveness of saxagliptin (Onglyza(R)) in type 2 diabetes in Sweden Prim Care Diabetes 2012; 6(2):127-36
Grzeszczak W, Czupryniak L, Kolasa K, Sciborski C, Lomon ID, McEwan P. The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland Diabetes Technol Ther 2012; 14(1):65-73
Masters S, Gordon J, Whitehead C, Davies O, Giles LC, Ratcliffe J. Coaching Older Adults and Carers to have their preferences Heard (COACH): A randomised controlled trial in an intermediate care setting (study protocol) Australas Med J 2012; 5(8):444-54
Neri L, McEwan P, Sennfalt K, Baboolal K. Characterizing the relationship between health utility and renal function after kidney transplantation in UK and US: a cross-sectional study Health Qual Life Outcomes 2012; 10:139
Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2
Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–2 Value Health 2012; 15(6):804-11
System tools for system change
Willis CD, Mitton C, Gordon J, Best A. System tools for system change BMJ Qual Saf 2012; 21(3):250-62
Publications for 2011
Townsend R, McEwan P, Kim R, Yuan Y. Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C Value Health 2011; 14(8):1068-77